Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | TNF | P01375 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834800 | 0.89 | TP53 (0.69) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL15568834 | 0.88 | POLB (0.74) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL8366932 | 0.87 | RAB9A (0.76) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL13186949 | 0.87 | HIF1A (0.67) | MEN1KMT2ALMNAMAPTTNF | |
| SCHEMBL12771528 | 0.85 | LMNA (0.69) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL6833621 | 0.81 | TNF (0.81) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL10089254 | 0.81 | VDR (0.61) | SMN1; SMN2MEN1KMT2ALMNATP53 | |
| SCHEMBL16756579 | 0.81 | TSHR (1.00) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL30582653 | 0.81 | TSHR (1.00) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL13144806 | 0.81 | CYP1A2 (0.80) | MEN1KMT2ALMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101628-B2 | Methods and composition of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | SMN1; SMN2 2247/4885MEN1 4880/4885KMT2A 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.